Cholesterol control in stroke prevention in Italy: A cross-sectional study in family practice

European Journal of Preventive Cardiology

Volumn 12, Issue 2, 2005, Pages 159-163

  Filippi, Alessandro ^a   Tragni, Elena ^b   Bignamini, Angelo A ^c   Sessa, Emiliano ^d   Merlini, Giovanni ^a   Brignoli, Ovidio ^a   Mazzaglia, Giampiero ^d   Catapano, Alberico L ^b  

^a Italian College of General Practitioners   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Post Graduated Sch of Hosp Pharm   (Italy)

^d Health Search Database   (Italy)

Author keywords

cholesterol; family practice; hypolipidaemic drugs; stroke

Indexed keywords

CHOLESTEROL; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DATA BASE; DYSLIPIDEMIA; FAMILY MEDICINE; GENERAL PRACTITIONER; HUMAN; ITALY; LIPID BLOOD LEVEL; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FAMILY PRACTICE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; ISCHEMIC ATTACK, TRANSIENT; ITALY; MALE; MIDDLE AGED; PROBABILITY; REGISTRIES; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 17644397338     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000161444.96302.cc     Document Type: Article

References (29)

1. World Health Organization. Making a difference. The World Health Report; 1999.
2. Gensini GF. SPREAD 2001 (editor): Ictus cerebrale: linee guida italiane di prevenzione e trattamento. Milano: Pubblicazioni Catel; 2001.
3. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14–22.
4. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346: 1647–1653.
5. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for multiple risk factor intervention trial. N Engl J Med 1989; 320: 904–910.
6. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313–321.
7. Heart Protection Study Collaborative Group. Effects of cholesterol lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757–767.
8. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001; 285: 2729–2735.
9. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999; 99: 216–223.
10. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995; 155: 50–55.
11. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Int Med 2003; 163: 669–676.
12. Gensini GF. SPREAD Stroke Prevention and Educational Awareness Diffusion (editor). Ictus cerebrale: linee guida italiane di prevenzione e trattamento. Milano: Pubblicazioni Catel; 2003.
13. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001; 32: 280–299.
14. Cricelli C, Mazzaglia G, Samani F, Marchi M, Sabatini A, Nardi R, et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med 2003; 25: 254–257.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
16. Adult Treatment Panel III. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486–2493.
17. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Blood Press 1998; 7: 262–269.
18. Blauw GJ, Lagaay AM, Smelt AH, Westendorp LG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28: 946–950.
19. Bucher HC, Griffith LE, Guyatt GH. Effect of HMG-CoA reductase inhibitors on stroke. A meta-analysis of randomized trials. Ann Intern Med 1998; 128: 89–95.
20. Di Mascio R, Marchioli R, Tognoni G. Cholesterol reduction and stroke recurrence: an overview of randomized clinical trials. Cerebrovasc Dis 2000; 10: 85–92.
21. Adams RJ, Chimowitz MI, Alpert JS, Awad IA, Cerqueria MD, Fayad P, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke. A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation 2003; 108: 1278–1290.
22. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423–1429.
23. Bullard M, Rowe B, Meurer D. Electronic Triage and Clinical Practice Guideline Tools: Combining Education with Point-of-care Applicability. Academic Emergency Medicine 2002; 9: 1060–1061.
24. Mant A, Rotem WC, Kehoe L, Kaye KI. Compliance with guidelines for continuity of care in therapeutics from hospital to community. Med J Aust 2001; 174: 277–280.
25. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993–1998. Br J Clin Pharmacol 2002; 53: 375–378.
26. Pearson TA, Laurora I, Chu H, Hafonek S. The Lipid Treatment Assessment Project (L-TAP). A multicentre survey, to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–467.
27. Hulscher MEJL, Wensing M, van der Weijden T, Grol R. Interventions to implement prevention in primary care. In: Cochrane Collaboration. The Cochrane Library, Issue 1, Oxford: Update Software; 2002.
28. Jamtvedt G, Young JM, Kristoffersen DT, Thomson O'Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes (Cochrane Review). In: Cochrane Collaboration. The Cochrane Library, Issue 3, Oxford: Update Software; 2003.
29. Filippi A, Sabatini A, Badioli L, Samani F, Mazzaglia G, Catapano A, et al. Effects of an automated electronic reminder in changing the antiplatelet drugs prescribing behaviour among Italian General Practitioners in diabetics patients: an intervention trial. Diabetes Care 2003; 26: 1497–1500.